Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $43.14

Key Points

• Arrowhead Pharmaceuticals, Inc. has received a consensus rating of "Buy" from analysts, with an average target price of $43.14.
• Insider James C. Hamilton sold 9,389 shares at an average price of $20.00, reducing his stake by 3.46% but still holding over 262,000 shares in the company.
• Institutional investors currently own 62.61% of Arrowhead Pharmaceuticals, with notable increases in holdings from firms like Wells Fargo and Barclays during the last quarter.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given an average recommendation of "Buy" by the nine research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $43.1429.

A number of equities research analysts have recently issued reports on the company. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Finally, Royal Bank Of Canada dropped their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research report on Friday, August 8th.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 9,389 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $20.00, for a total value of $187,780.00. Following the transaction, the insider directly owned 262,122 shares in the company, valued at approximately $5,242,440. This represents a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Virtus Advisers LLC acquired a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $34,000. GAMMA Investing LLC lifted its holdings in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $49,000. Nisa Investment Advisors LLC lifted its holdings in Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 1,308 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 3,763 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR traded down $0.31 during trading hours on Friday, hitting $22.03. 2,388,669 shares of the stock were exchanged, compared to its average volume of 2,433,496. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $27.34. The firm's fifty day moving average price is $17.71 and its 200 day moving average price is $16.02. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The company has a market cap of $3.05 billion, a P/E ratio of -17.21 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same period in the prior year, the business posted ($1.38) EPS. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.